ErbB2、VEGF和β-catenin在颌骨骨肉瘤组织中的表达及其临床意义  

Expressions and clinical significance of ErbB2,VEGF and β-catenin in jaw osteosarcoma patients

作　　者：韦山良[1] 江献芳[1] 谢庆条[1] 巫家晓[1] 

机构地区：[1]广西医科大学附属口腔医院口腔颌面外科,南宁530021

出　　处：《广西医科大学学报》2017年第9期1289-1292,共4页Journal of Guangxi Medical University

基　　金：广西医疗卫生适宜技术研究与开发项目(No.S201411-01);广西高校科学技术研究项目(No.KY2015LX059);广西壮族自治区卫生厅科研课题(No.Z2014092)

摘　　要：目的:探讨ErbB2、血管内皮生长因子(VEGF)和β-链蛋白(β-catenin)在骨肉瘤组织中的表达及其与骨肉瘤分化程度之间的关系。方法:应用免疫组织化学法(S-P法)检测30例骨肉瘤患者组织中ErbB2、VEGF和β-catenin的表达,并比较高分化组和低分化组ErbB2、VEGF和β-catenin表达的差异。结果:30例骨肉瘤患者中,ErbB2、VEGF和β-catenin阳性表达率分别为57%、93%、60%。在高、低分化类型骨肉瘤病例中,ErbB2阳性表达率分别为60%、50%;VEGF阳性表达率分别为90%、90%;β-catenin阳性表达率分别为70%、60%,两组以上指标比较,差异均无统计学意义(均P>0.05)。结论:ErbB2、VEGF和β-catenin在骨肉瘤组织中呈高表达,但其表达与肿瘤分化程度无关,检测ErbB2、VEGF和β-catenin的阳性表达率也许可以作为判断骨肉瘤发生和发展的重要指标。Objective： To investigate the expressions and clinical significance of ErbB2, VEGF and β-catenin in jaw osteosarcoma patients. Methods： The osteosarcoma tissues from 30 cases of patients were collected and divid- ed into high differentiation group and low differentiation group according to the postoperative pathological diagno- sis. The expressions of ErbB2, VEGF and β-catenin were determined by immunohistochemical staining and com- pared between the two groups. Results： The positive rates of ErbB2, VEGF and β-catenin in these patients were 57%, 93% and 60%, respectively. ErbB2 positive expression rates in high differentiation group and low differentia- tion group were respectively 60% and 50%, VEGF were both 90%, and β-catenin were 70% and 60%. There were no significant differences in the positive expression rates of ErbB2, VEGF and β-eatenin between the two groups （P〉0. 05）. Conclusion： The expressions of ErbB2, VEGF and β-catenin in jaw osteosarcoma patients were up-regulated, but were not related to tumor differentiation degree. The positive rates of ErbB2, VEGF and β-atenin expressions could be an important indicator for judging the occurrence and development of osteosarcoma.

关 键 词：Erb B2 VEGF Β-CATENIN 颌骨骨肉瘤 

分 类 号：R739.8[医药卫生—肿瘤]